enVVeno Medical Corporation NVNO
5.57 USD -0.20 (-3.47%)
Regular-session close
5.57 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
5.43 Day range 5.85
5.43 52-week range 14.67
- YTD
- -50.40%
- 1 year
- -49.82%
News
benzinga.com enVVeno Medical Q3 EPS $(6.29) Misses $(3.27) Estimate enVVeno Medical (NASDAQ:NVNO) reported quarterly losses of $(6.29) per share which missed the analyst consensus estimate of $(3.27) by 92.35 percent. This is a 21.86 percent increase over losses of…
accessnewswire.com enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial Leading venous interventionalist Karen B. Garby, MD, DABVLM, RPhS, to present the enVVe® System, a minimally invasive replacement venous valve currently being evaluated in a U.S. pivotal study An…
accessnewswire.com enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand Access the video webcast here IRVINE, CA / ACCESS Newswire / September 11, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that its pre-recorded…
accessnewswire.com enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference Video Webcast Now Available Here IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced that Robert Berman,…
accessnewswire.com Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling…
accessnewswire.com enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway…
accessnewswire.com enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market Watch the "What This Means" video here…
accessnewswire.com enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting…
accessnewswire.com enVVeno Medical to Present in the Webull Corporate Connect Webinar Series - Live webcast on Wednesday, June 24th at 2:00 PM ET - Access the event here IRVINE, CA / ACCESS Newswire / June 22, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"),a…
accessnewswire.com enVVeno Medical to Participate in the Virtual Investor Closing Bell Series Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ET Register here IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical…
accessnewswire.com enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve IDE approval positions enVVeno to advance what could become the first effective treatment option for…
accessnewswire.com enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System Company ended the first quarter with approximately $25 million in cash and investments Capital on hand should fund operations through multiple key milestones into Q3 2027 Company recently received…
accessnewswire.com enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial Clinical site activation and patient enrollment expected to commence later this year Large unmet clinical need for…
accessnewswire.com enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System Company accelerated development of the enVVe® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiation Strong financial position expected to provide an operating…
globenewswire.com NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives NEWPORT BEACH, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- NorthStrive Fund II LP (“NorthStrive Fund II”), a subsidiary of NorthStrive Companies Inc., headquartered in Newport Beach, California, and…
defenseworld.net Reviewing Pressure BioSciences (OTCMKTS:PBIO) & enVVeno Medical (NASDAQ:NVNO) Pressure BioSciences (OTCMKTS:PBIO - Get Free Report) and enVVeno Medical (NASDAQ: NVNO - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare…
defenseworld.net Head to Head Analysis: LENSAR (NASDAQ:LNSR) versus enVVeno Medical (NASDAQ:NVNO) LENSAR (NASDAQ: LNSR - Get Free Report) and enVVeno Medical (NASDAQ: NVNO - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two…
accessnewswire.com enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed Reports Cash and Investments of approximately $28 million as of the Year Ended December…
defenseworld.net enVVeno Medical Stock Set to Reverse Split on Tuesday, January 20th (NASDAQ:NVNO) enVVeno Medical Corporation (NASDAQ: NVNO)'s stock is going to reverse split on the morning of Tuesday, January 20th. The 1-35 reverse split was recently announced. The number of shares owned by…
accessnewswire.com enVVeno Medical Announces Reverse Stock Split IRVINE, CA / ACCESS Newswire / January 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company's Board of Directors has approved a…
accessnewswire.com enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, December 3rd at 4:00 PM ET IRVINE, CA / ACCESS Newswire / November 26, 2025 / enVVeno Medical…
